Adverse events should be reported.
Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store.
Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on 01753 627777.
A link to the prescribing information can be found in the header.

Dysport® (Clostridium botulinum type A toxin-haemagglutinin complex) is indicated in adults for symptomatic treatment of spasmodic torticollis

Please click here to see the full therapeutic indications.

Cervical Dystonia

Tackling the capacity challenge in your clinics with Dysport®

7 minutes

Dr Jonathan Evans discusses Dysport® time to retreatment in clinical trials and how moving to Dysport® may allow adult patients with cervical dystonia to avoid unnecessary appointments and contribute to increasing clinic capacity

DYS-UK-008738

Making sense of the changing NHS and funding flows

12 minutes

Dr Judy Willits discusses how the NHS payment scheme has evolved and what the changes could mean for your botulinum toxin services.

DYS-UK-008730